Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Operating Expenses of $1.8 billion for Q1 2026, down 13.61% year-over-year from $2.1 billion in Q1 2025, and down 6.82% quarter-over-quarter from $2.0 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- In Q1 2026, Operating Expenses fell 13.61% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $7.5 billion (down 36.36% YoY), while the FY2025 annual figure was $7.8 billion, down 30.44% from the prior year.
- Operating Expenses for Q1 2026 stood at $1.8 billion, down from $2.0 billion in the prior quarter.
- The five-year high for Operating Expenses was $6.2 billion in Q2 2024, with the low at $1.1 billion in Q1 2022.
- The 5-year median for Operating Expenses is $1.6 billion (2023), against an average of $1.9 billion.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 319.98% in 2024, then tumbled 70.56% in 2025.
- Vertex Pharmaceuticals' Operating Expenses stood at $1.3 billion in 2022, then increased by 20.49% to $1.5 billion in 2023, then grew by 23.33% to $1.9 billion in 2024, then climbed by 5.2% to $2.0 billion in 2025, then slipped by 6.82% to $1.8 billion in 2026.
- Business Quant data shows VRTX's Operating Expenses at $1.8 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 367.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.09 Bn |
| Mar 31, 2026 | 1.85 Bn |
| Dec 31, 2025 | 1.98 Bn |
| Sep 30, 2025 | 1.89 Bn |
| Jun 30, 2025 | 1.81 Bn |
| Mar 31, 2025 | 2.14 Bn |
| Dec 31, 2024 | 1.89 Bn |
| Sep 30, 2024 | 1.66 Bn |
| Jun 30, 2024 | 6.16 Bn |
| Mar 31, 2024 | 1.55 Bn |
| Dec 31, 2023 | 1.53 Bn |
| Sep 30, 2023 | 1.45 Bn |
| Jun 30, 2023 | 1.47 Bn |
| Mar 31, 2023 | 1.60 Bn |
| Dec 31, 2022 | 1.27 Bn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.09 Bn |
| Mar 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 1.19 Bn |
| Sep 30, 2021 | 929.60 Mn |